Welcome to iPraxic.org

RBAC adjusts the activity of the immune system as needed.

In vitro studies have found that RBAC inhibits the replication of the HIV virus.

In vitro studies show RBAC increases the number of helper T cells in the presence of the HIV virus.

RBAC may calm an overactive immune system in patients with autoimmune diseases.

RBAC can increase the activity of NK cells, according to human clinical research in cancer patients.

RBAC increases the chances of long-term stabilization or remission of cancer when used in conjunction with conventional treatment.

Several human clinical trials have shown that RBAC improves the quality of life of late-stage cancer patients.

RBAC increases the survival rate of stage III and IV cancer patients by 50%, as shown by a two-year study of over 100 patients.

RBAC supports the body’s production of cytokines, as demonstrated by in vitro and human clinical trials.

A study in elderly adults found that RBAC increases resistance to the common cold.

RBAC cuts the duration of common cold symptoms in half, according to a study in elderly adults.

Case studies have found that RBAC improves symptoms – such as pain, poor sleep, swelling and decreased appetite – in patients with rheumatism.

RBAC possesses antioxidant and anti-inflammatory activity.

RBAC does not lose effectiveness with prolonged use.

Upcoming seminar information will be announced soon.

iPraxic

These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.